SOUTH SAN FRANCISCO, Calif.,
Dec. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
(NASDAQ: TTNP) ("the "Company") today announced that on
December 15, 2020, it received a
notification letter from The Nasdaq Stock Market LLC ("Nasdaq")
confirming that the Company has regained compliance with Nasdaq's
minimum bid price requirement and is in compliance with all
applicable listing standards. Therefore, the scheduled hearing
before the Nasdaq Hearings Panel has been cancelled and the
Company's common stock will continue to trade on the Nasdaq Capital
Market.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in
South San Francisco, CA, is a
development stage company developing proprietary therapeutics with
its ProNeura® long-term, continuous drug delivery technology. The
ProNeura technology has the potential to be used in developing
products for treating a number of chronic conditions, where
maintaining consistent, around-the-clock blood levels of medication
may benefit the patient and improve medical outcomes. For more
information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to our
ability to raise capital, the winding down of U.S. commercial
activities related to Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACTS:
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-301193972.html
SOURCE Titan Pharmaceuticals, Inc.